<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="4-part\PMC7186774\results\search\tropicalVirus\results.xml">
  <result pre=": italic;} EBioMedicineEBioMedicineEBioMedicine2352-3964Elsevier pmcid: 7186774S2352-3964(20)30113-4 doi: 10.1016/j.ebiom.2020.102738102738 : Research paper" exact="Zika" post="virus envelope nanoparticle antibodies protect mice without risk of"/>
  <result pre="access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract Background" exact="Zika" post="virus (ZIKV), an arbovirus capable of causing neurological abnormalities,"/>
  <result pre="recognised human pathogen, for which a vaccine is required. As" exact="ZIKV" post="antibodies can mediate antibody-dependent enhancement (ADE) of dengue virus"/>
  <result pre="mediate antibody-dependent enhancement (ADE) of dengue virus (DENV) infection, a" exact="ZIKV" post="vaccine must not only protect against ZIKV but must"/>
  <result pre="(DENV) infection, a ZIKV vaccine must not only protect against" exact="ZIKV" post="but must also not sensitise vaccinees to severe dengue."/>
  <result pre="sensitise vaccinees to severe dengue. Methods The N-terminal 80% of" exact="ZIKV" post="envelope protein (80E) was expressed in Pichia pastoris and"/>
  <result pre="BALB/c and C57BL/6 Stat2−/− mice, respectively. Its capacity to enhance" exact="DENV" post="and ZIKV infection was assessed in AG129 and C57BL/6"/>
  <result pre="C57BL/6 Stat2−/− mice, respectively. Its capacity to enhance DENV and" exact="ZIKV" post="infection was assessed in AG129 and C57BL/6 Stat2−/− mice,"/>
  <result pre="0.01, Mantel–Cox test), and did not exacerbate sub-lethal DENV-2 or" exact="ZIKV" post="challenges in vivo. Interpretation Yeast-expressed ZIKV-80E, which forms highly"/>
  <result pre="Interpretation Yeast-expressed ZIKV-80E, which forms highly immunogenic EDIII-displaying NPs, elicits" exact="ZIKV" post="EDIII-specific antibodies capable of offering significant protection in vivo,"/>
  <result pre="without the potential risk of ADE upon subsequent DENV-2 or" exact="ZIKV" post="infection. This offers a promising vaccine candidate for further"/>
  <result pre="supported partly by ICGEB, India, and by NIAID, USA. Keywords" exact="Zika" post="virus vaccine VLPs Nanoparticles Pichia pastoris;Dengue virus Antibody-dependent enhancement"/>
  <result pre="study Currently there is no vaccine to prevent infection by" exact="Zika" post="virus, a mosquito-borne flavivirus closely related to dengue viruses."/>
  <result pre="mosquito-borne flavivirus closely related to dengue viruses. The recent explosive" exact="Zika" post="virus epidemics associated with severe neurological abnormalities, especially in"/>
  <result pre="observation, together with the known serological cross-reactivity that exists between" exact="Zika" post="and dengue viruses, has led to the hypothesis that"/>
  <result pre="dengue virus antibodies may have helped enhance the severity of" exact="Zika" post="virus disease in these epidemics. Human sera from dengue"/>
  <result pre="in these epidemics. Human sera from dengue patients can enhance" exact="Zika" post="virus infection both in cultured cells and mice. Likewise,"/>
  <result pre="infection both in cultured cells and mice. Likewise, sera from" exact="Zika" post="virus-infected patients can enhance dengue virus infection of cells"/>
  <result pre="it is possible to create a recombinant nanoparticle vaccine for" exact="Zika" post="in the absence of the pre-membrane protein implicated in"/>
  <result pre="lethal challenge, does not cause enhancement of either dengue or" exact="Zika" post="virus infection in mice. Implications of all the available"/>
  <result pre="Implications of all the available evidence None of the other" exact="Zika" post="vaccine candidates being developed currently is designed to eliminate"/>
  <result pre="to eliminate the induction of cross-reactive, infection-enhancing antibodies. An ideal" exact="Zika" post="vaccine must induce antibodies which can prevent Zika virus"/>
  <result pre="An ideal Zika vaccine must induce antibodies which can prevent" exact="Zika" post="virus infection, while at the same time being incapable"/>
  <result pre="severity of eventual dengue infection. As the incidence of new" exact="Zika" post="infections is almost absent at the current time, clinical"/>
  <result pre="of vaccine candidates is not possible. Active pre-clinical development of" exact="Zika" post="virus-blocking, infection enhancement-free vaccine candidates will ensure their availability"/>
  <result pre="vaccine candidates will ensure their availability for efficacy testing when" exact="Zika" post="virus appears again. Alt-text: Unlabelled box 1 Introduction Zika"/>
  <result pre="when Zika virus appears again. Alt-text: Unlabelled box 1 Introduction" exact="Zika" post="virus (ZIKV) is a mosquito-borne flavivirus, phylogenetically related to"/>
  <result pre="Zika virus (ZIKV) is a mosquito-borne flavivirus, phylogenetically related to" exact="West Nile" post="virus, Yellow fever virus, Japanese encephalitis virus, tick-borne encephalitis"/>
  <result pre="is a mosquito-borne flavivirus, phylogenetically related to West Nile virus," exact="Yellow fever" post="virus, Japanese encephalitis virus, tick-borne encephalitis virus and dengue"/>
  <result pre="NS2a, NS2b, NS3, NS4a, NS4b and NS5 (Fig. 1a) [2]." exact="ZIKV" post="is spread to humans by Aedes mosquitoes and has"/>
  <result pre="with mild and self-limiting fever, akin to dengue fever [3,4]." exact="ZIKV" post="may also be transmitted between humans sexually [5] or"/>
  <result pre="also be transmitted between humans sexually [5] or vertically [6,7]." exact="ZIKV" post="outbreaks have been documented in recent times starting from"/>
  <result pre="Africa and the Americas [3,8,9]. More severe clinical manifestations of" exact="ZIKV" post="infection became apparent in the Brazilian outbreaks during 2015."/>
  <result pre="in the Brazilian outbreaks during 2015. Exposure of fetuses to" exact="ZIKV" post="in the first trimester of pregnancy has been linked"/>
  <result pre="defects including microcephaly [7,[10], [11], [12]]. On the other hand," exact="ZIKV" post="infection in adults appears to lead to an autoimmune"/>
  <result pre="These neurological abnormalities have been linked to the capacity of" exact="ZIKV" post="to infect human neural progenitor cells [14]. ZIKV infections"/>
  <result pre="capacity of ZIKV to infect human neural progenitor cells [14]." exact="ZIKV" post="infections are beginning to be reported in India. It"/>
  <result pre="than 2 billion people live in areas considered suitable for" exact="ZIKV" post="transmission [15]. The incidence of ZIKV infections has almost"/>
  <result pre="areas considered suitable for ZIKV transmission [15]. The incidence of" exact="ZIKV" post="infections has almost totally vanished as of now and"/>
  <result pre="a decade [16]. It has been suggested that a preventive" exact="ZIKV" post="vaccine is an urgent need [17] and that this"/>
  <result pre="this lull period should be taken advantage of to develop" exact="ZIKV" post="vaccine candidates for possible future use [18]. Fig. 1"/>
  <result pre="and purification of ZIKV-80E antigen. (a) Schematic representation of the" exact="ZIKV" post="polyprotein. Proteins prM and E are indicated by black"/>
  <result pre="arrow on the right indicates the position of the recombinant" exact="ZIKV" post="E protein. ZIKV vaccine development is complicated by the"/>
  <result pre="right indicates the position of the recombinant ZIKV E protein." exact="ZIKV" post="vaccine development is complicated by the existence of the"/>
  <result pre="Fc gamma receptors (Fcγ-R) and increase tissue virus load [19]." exact="ZIKV" post="is not only genetically and antigenically similar to DENVs,"/>
  <result pre="shares the same mosquito vector [20]. The high seroprevalence of" exact="DENV" post="in areas [21], [22], [23] that witnessed the recent"/>
  <result pre="DENV in areas [21], [22], [23] that witnessed the recent" exact="ZIKV" post="epidemics, has raised speculation that pre-existing DENV antibodies may"/>
  <result pre="witnessed the recent ZIKV epidemics, has raised speculation that pre-existing" exact="DENV" post="antibodies may have been responsible for ADE of ZIKV"/>
  <result pre="pre-existing DENV antibodies may have been responsible for ADE of" exact="ZIKV" post="infection, resulting in more severe clinical disease [24,25]. The"/>
  <result pre="ZIKV-induced antibodies may possess the potential to promote ADE of" exact="DENV" post="infection, which in turn could lead to severe dengue"/>
  <result pre="lead to severe dengue disease, poses a significant hurdle to" exact="ZIKV" post="vaccine development. Numerous ZIKV vaccine candidates, employing multiple technologies"/>
  <result pre="disease, poses a significant hurdle to ZIKV vaccine development. Numerous" exact="ZIKV" post="vaccine candidates, employing multiple technologies and platforms, are being"/>
  <result pre="recombinant measles virus-vectored vaccine and several plasmid DNA-based and inactivated" exact="ZIKV" post="candidates are in phase 1 trials, with the mRNA"/>
  <result pre="most protein-based vaccine candidates are designed to encode the two" exact="ZIKV" post="structural proteins, prM and E [28], [29], [30]. The"/>
  <result pre="neutralising antibodies (nAbs). Just like its other flaviviral counterparts, the" exact="ZIKV" post="E protein is also organized into three distinct domains,"/>
  <result pre="microscopic analyses reveal that the overall structure of the mature" exact="ZIKV" post="particle is similar to that of other flaviviruses [35,36]."/>
  <result pre="other flaviviruses [35,36]. Comparative sequence analysis of ancestral and contemporary" exact="ZIKV" post="strains has led to the identification of a single"/>
  <result pre="presumably confers tropism for neural progenitor cells [38]. Co-expression of" exact="ZIKV" post="prM and E proteins in insect [39] and mammalian"/>
  <result pre="genome. We recently found that the amino-terminal 80% of the" exact="DENV" post="E molecule (DENV-80E), of all four serotypes, expressed in"/>
  <result pre="as platforms for the efficient display of EDIII. Like the" exact="DENV" post="EDIIIs, ZIKV EDIII is also the target of potent"/>
  <result pre="for the efficient display of EDIII. Like the DENV EDIIIs," exact="ZIKV" post="EDIII is also the target of potent nAbs. ZIKV"/>
  <result pre="EDIIIs, ZIKV EDIII is also the target of potent nAbs." exact="ZIKV" post="EDIII-specific monoclonal antibodies (mAbs) from mice [31] as well"/>
  <result pre="as humans [32,47] have been documented to not only neutralise" exact="ZIKV" post="in vitro, but also to confer significant protection against"/>
  <result pre="ZIKV in vitro, but also to confer significant protection against" exact="ZIKV" post="challenge in vivo. Taken together, this prompted us to"/>
  <result pre="this prompted us to explore if the N-terminal 80% of" exact="ZIKV" post="E protein (hereinafter referred to as ZIKV-80E), expressed using"/>
  <result pre="wanted to investigate whether such ZIKV-80E NP-induced antibodies would enhance" exact="DENV" post="and ZIKV infections in vivo. This paper describes our"/>
  <result pre="investigate whether such ZIKV-80E NP-induced antibodies would enhance DENV and" exact="ZIKV" post="infections in vivo. This paper describes our efforts to"/>
  <result pre="Genetic Engineering and Biotechnology (ICGEB), New Delhi (ICGEB/IAEC/08/2016/RGP-14 and ICGEB/IAEC/02042019/RGP-2)." exact="DENV" post="type 2 (DENV-2) challenge experiments using AG129 mice were"/>
  <result pre="coli plasmids for expression of maltose-binding protein (MBP) fusions of" exact="ZIKV" post="EDIII [48] and DENV EDIIIs [49] have been mentioned"/>
  <result pre="of maltose-binding protein (MBP) fusions of ZIKV EDIII [48] and" exact="DENV" post="EDIIIs [49] have been mentioned before. Vero cells (ATCC"/>
  <result pre="serum, at 37 °C in a humidified 10% CO2 incubator." exact="ZIKV" post="reporter virus particles (RVPs), containing the structural proteins (prM"/>
  <result pre="Uganda 1947 (MR766) and Puerto Rico 2015 (PRVABC59) strains of" exact="ZIKV" post="have been described before [50]. DENV-1 (WP 74), DENV-2"/>
  <result pre="[49,51]. mAb 24A12, specific to DENVs 1–3 EDIIIs [52] and" exact="ZIKV" post="EDIII [48], mAb 4G2 [53], specific to the flavivirus"/>
  <result pre="[53], specific to the flavivirus fusion loop epitope (FLE), the" exact="ZIKV" post="EDIII-specific murine mAbs [31], ZV48 (RRID: AB_2725796), ZV-2, and"/>
  <result pre="analysed by indirect enzyme-linked immunosorbent assay (ELISA) (Methods S1), using" exact="ZIKV" post="mAbs ZV48, ZV-2, ZV-67 and ZKA-64 [31,32]. NP formation"/>
  <result pre="total antibody titres by indirect ELISA and nAb titres by" exact="ZIKV" post="and DENV virus neutralisation assays. Polyclonal anti-DENV-2 antiserum as"/>
  <result pre="titres by indirect ELISA and nAb titres by ZIKV and" exact="DENV" post="virus neutralisation assays. Polyclonal anti-DENV-2 antiserum as a control"/>
  <result pre="day 28, pooled and nAb titres determined against all four" exact="DENV" post="serotypes. Additional details are provided in Methods S2 (Supplementary"/>
  <result pre="DENV-3 and DENV-4) and five different 80E proteins (corresponding to" exact="ZIKV" post="and DENV serotypes 1–4), as the capture antigens (Methods"/>
  <result pre="DENV-4) and five different 80E proteins (corresponding to ZIKV and" exact="DENV" post="serotypes 1–4), as the capture antigens (Methods S1). Background"/>
  <result pre="(v7.0) software. 2.9 Determination of nAb titres in immune sera" exact="ZIKV" post="nAb titres in immune sera against two different ZIKV"/>
  <result pre="sera ZIKV nAb titres in immune sera against two different" exact="ZIKV" post="strains (MR766 and PRVABC59) were determined by using an"/>
  <result pre="fluorescence activated cell sorting (FACS)-based method, initially developed for determining" exact="DENV" post="nAb titres [51]. Serial dilutions of heat-inactivated (56 °C/30"/>
  <result pre="and titrated on Vero cells as described (Methods S1). The" exact="ZIKV" post="neutralisation titre, NT50, is defined as the reciprocal of"/>
  <result pre="ZIKV-infected cells in the absence of serum taken as 100%." exact="ZIKV" post="nAb titres were also determined using single-round infectious ZIKV"/>
  <result pre="100%. ZIKV nAb titres were also determined using single-round infectious" exact="ZIKV" post="RVPs, encoding Renilla luciferase reporter, as described earlier [48]."/>
  <result pre="the serum dilution capable of causing a 50% reduction in" exact="ZIKV" post="RVP-expressed luciferase activity, with reference to the luciferase activity"/>
  <result pre="luciferase activity, with reference to the luciferase activity expressed by" exact="ZIKV" post="RVP in the absence of immune serum, taken as"/>
  <result pre="the absence of immune serum, taken as 100%. In some" exact="ZIKV" post="RVP experiments, the immune serum was subjected to pre-depletion"/>
  <result pre="was subjected to pre-depletion on a chromatographic matrix on which" exact="ZIKV" post="EDIII was immobilised (Methods S1). DENV-specific nAb titres were"/>
  <result pre="488 conjugate to detect DENV-infected cells, as before [49,51]. For" exact="DENV" post="nAbs, NT50 titre of the immune serum is defined"/>
  <result pre="cells with reference to the number of cells infected by" exact="DENV" post="in absence of immune serum, taken as 100%. 2.10"/>
  <result pre="× 103 plaque forming units (PFUs) of the highly pathogenic" exact="ZIKV" post="strain MR766. A group of mice that received neither"/>
  <result pre="group of mice that received neither immune plasma nor the" exact="ZIKV" post="challenge was included for comparison. Mice were bled on"/>
  <result pre="The capacity of polyclonal anti-ZIKV-80E antisera to promote ADE of" exact="DENV" post="in vitro was evaluated using the FcγII-R-expressing K562 cell"/>
  <result pre="line. The ability of these antibodies to promote ADE of" exact="DENV" post="in vivo was assessed by monitoring survival of interferon"/>
  <result pre="assessed for its ability to mediate ADE of a non-pathogenic" exact="ZIKV" post="infection in vivo, using C57BL/6 Stat2−/− mouse model [24,50]"/>
  <result pre="synthetic ZIKV-80E gene based on the previous design of the" exact="DENV" post="80E genes. Thus, the ZIKV-80E gene (codon-optimised for expression"/>
  <result pre="P. pastoris) encoded the last 34 aa residues of the" exact="ZIKV" post="prM protein followed by the first 403 aa residues"/>
  <result pre="protein followed by the first 403 aa residues of the" exact="ZIKV" post="E protein (Fig. 1a and b). These sequences were"/>
  <result pre="least 99% sequence identity with the E proteins of Asian" exact="ZIKV" post="strains, at least 96% sequence identity with the E"/>
  <result pre="least 96% sequence identity with the E proteins of African" exact="ZIKV" post="strains and 55–57% sequence identity with respect to E"/>
  <result pre="(Fig. 1d). This revealed that recombinant ZIKV-80E protein, like its" exact="DENV" post="counterparts, is also exclusively present in the insoluble P"/>
  <result pre="2a). This band was recognised by mAb 24A12, which recognises" exact="ZIKV" post="EDIII [48] in a Western blot (Fig. 2b). As"/>
  <result pre="previously observed that purified recombinant DENV-80E proteins, of all four" exact="DENV" post="serotypes, when expressed using the P. pastoris host system"/>
  <result pre="interesting given that there are several reports which suggest that" exact="ZIKV" post="VLPs are formed only when prM and E proteins"/>
  <result pre="epitopes map to EDIII, we focused on a set of" exact="ZIKV" post="EDIII-specific mAbs and carried out indirect ELISAs using the"/>
  <result pre="ZV-67, but not by ZV-2. Their binding sites on the" exact="ZIKV" post="E protein have been mapped using recombinant protein-binding studies"/>
  <result pre="the C–C’ loop and the lateral ridge (LR), respectively of" exact="ZIKV" post="EDIII. Of these, the LR epitope is quite complex"/>
  <result pre="The efficient recognition by mAb ZV-67, a potent neutraliser of" exact="ZIKV" post="infectivity, suggests that the antigenic integrity of the LR"/>
  <result pre="The binding of mAb ZV-48 (also a strong neutraliser of" exact="ZIKV" post="infectivity, but not as potent as ZV-67), which recognises"/>
  <result pre="C–C’ loop, suggest subtle difference(s) between ZIKV-80E NPs and the" exact="ZIKV" post="particle, as the C–C’ loop is not predicted to"/>
  <result pre="neutraliser, and also not predicted to be accessible on the" exact="ZIKV" post="particle [35,36], was not detectable on the ZIKV-80E NPs"/>
  <result pre="a human mAb, ZKA-64, a highly potent nAb, specific to" exact="ZIKV" post="EDIII [32]. Interestingly, none of these ZIKV mAbs recognised"/>
  <result pre="nAb, specific to ZIKV EDIII [32]. Interestingly, none of these" exact="ZIKV" post="mAbs recognised ZIKV EDIII displayed on HBV S-based VLPs,"/>
  <result pre="ZIKV EDIII [32]. Interestingly, none of these ZIKV mAbs recognised" exact="ZIKV" post="EDIII displayed on HBV S-based VLPs, providing an explanation"/>
  <result pre="displayed on HBV S-based VLPs, providing an explanation for why" exact="ZIKV" post="EDIII displayed on HBV S VLPs elicits very modest"/>
  <result pre="ZIKV EDIII displayed on HBV S VLPs elicits very modest" exact="ZIKV" post="nAb titres [48]. As expected none of the ZIKV"/>
  <result pre="modest ZIKV nAb titres [48]. As expected none of the" exact="ZIKV" post="mAbs recognised DSV4 VLPs (which display the EDIIIs of"/>
  <result pre="recognised DSV4 VLPs (which display the EDIIIs of all four" exact="DENV" post="serotypes [49]) as well as DENV-2-80E NPs [43]. However,"/>
  <result pre="[43]. However, the cross-reactive mAb 24A12 recognised EDIII moieties of" exact="ZIKV" post="and DENV-2, regardless of the particle platform. We also"/>
  <result pre="reactivity towards ZIKV-80E NPs, suggesting that in these NPs the" exact="ZIKV" post="E FLE is not accessible. Taken collectively, the mAb"/>
  <result pre="from duplicate assays of one experiment. bZika subunit vaccine, with" exact="ZIKV" post="EDIII displayed on HBV S-based VLPs [48]. cDengue subunit"/>
  <result pre="is a flavivirus cross-reactive mAb capable of recognising EDIIIs of" exact="ZIKV" post="[48] as well as DENVs 1–3 [53]. fThis pan-flavivirus-specific"/>
  <result pre="indirect ELISA. Consistent with the antigenic similarity which exists between" exact="ZIKV" post="E and the E proteins of the four DENV"/>
  <result pre="between ZIKV E and the E proteins of the four" exact="DENV" post="serotypes (Supplementary File, Fig. S1), we observed that the"/>
  <result pre="more than an order of magnitude lower than those against" exact="ZIKV" post="E NPs (Supplementary File, Fig. S3b). Fig. 3 Determination"/>
  <result pre="on day 38 using P. pastoris-produced purified 80E NPs of" exact="ZIKV" post="(purple), DENV-1 (magenta), DENV-2 (green), DENV-3 (blue) and DENV-4"/>
  <result pre="shown depict one of two independent experiments. (d) Determination of" exact="ZIKV" post="nAb titres in ZIKV-80E NP-immunised mice using FACS neutralisation"/>
  <result pre="heat-inactivated immune sera collected on day 38 were titrated against" exact="ZIKV" post="MR766 (solid purple curve) and ZIKV PRVABC59 (dashed purple"/>
  <result pre="38 were titrated against ZIKV MR766 (solid purple curve) and" exact="ZIKV" post="PRVABC59 (dashed purple curve). In parallel, mock-immune serum was"/>
  <result pre="parallel, mock-immune serum was similarly titrated against the same two" exact="ZIKV" post="strains (MR766: solid grey curve; PRVABC59: dashed grey curve)."/>
  <result pre="(MR766: solid grey curve; PRVABC59: dashed grey curve). Data depict" exact="ZIKV" post="infection (%) as a function of serum dilution. The"/>
  <result pre="function of serum dilution. The horizontal dashed line denotes 50%" exact="ZIKV" post="infection. Next, we carried out an indirect ELISA using"/>
  <result pre="EDIII proteins (as MBP fusions) corresponding to the five viruses," exact="ZIKV" post="and DENVs 1–4 (Fig. 3c). This revealed that the"/>
  <result pre="(Fig. 3c). This revealed that the antibody titres against recombinant" exact="ZIKV" post="EDIII protein were quite high (serum log10 titres were"/>
  <result pre="question: what proportion of these antibodies would manifest cross-reactivity towards" exact="DENV" post="EDIIIs? We addressed this by replacing ZIKV EDIII with"/>
  <result pre="manifest cross-reactivity towards DENV EDIIIs? We addressed this by replacing" exact="ZIKV" post="EDIII with DENV EDIII proteins as the coating antigen"/>
  <result pre="DENV EDIIIs? We addressed this by replacing ZIKV EDIII with" exact="DENV" post="EDIII proteins as the coating antigen in indirect ELISA"/>
  <result pre="antigen in indirect ELISA (Fig. 3c). The data revealed that" exact="DENV" post="EDIII cross-reactive titres were virtually indiscernible for DENV serotypes"/>
  <result pre="revealed that DENV EDIII cross-reactive titres were virtually indiscernible for" exact="DENV" post="serotypes 1 and 3 and significantly lower (p&amp;lt;0.0001) for"/>
  <result pre="and significantly lower (p&amp;lt;0.0001) for the remaining serotypes, compared to" exact="ZIKV" post="EDIII-specific titres (Supplementary File, Fig. S3b). Collectively the data"/>
  <result pre="conclusion that ZIKV-80E NP-elicited antibodies are predominantly (≥90%) specific to" exact="ZIKV" post="EDIII. We interpret this as a reflection of efficient"/>
  <result pre="with the efficient recognition of EDIII on ZIKV-80E NPs by" exact="ZIKV" post="EDIII-specific mAbs above (Table 1). The low levels (≤10%)"/>
  <result pre="ELISA titers against recombinant 80E and EDIII proteins corresponding to" exact="ZIKV" post="and DENV (Supplementary File, Fig. S4). We next evaluated"/>
  <result pre="against recombinant 80E and EDIII proteins corresponding to ZIKV and" exact="DENV" post="(Supplementary File, Fig. S4). We next evaluated if the"/>
  <result pre="the infectivity of ZIKV. This was addressed using a FACS-based" exact="ZIKV" post="neutralisation assay. In this experiment we tested the capacity"/>
  <result pre="anti-ZIKV-80E NP antisera to block the infectivity of two different" exact="ZIKV" post="strains: the highly pathogenic MR766 strain and the mildly"/>
  <result pre="pathogenic MR766 strain and the mildly pathogenic PRVABC59. Both these" exact="ZIKV" post="strains were efficiently blocked by the antibodies induced by"/>
  <result pre="was ineffective against either virus (NT50 &amp;lt;10). We also measured" exact="ZIKV" post="nAb titres of these sera using ZIKV RVPs, which"/>
  <result pre="We also measured ZIKV nAb titres of these sera using" exact="ZIKV" post="RVPs, which are identical to ZIKV on the outside"/>
  <result pre="of these sera using ZIKV RVPs, which are identical to" exact="ZIKV" post="on the outside and infect susceptible cells once, but"/>
  <result pre="encode Renilla luciferase reporter whose activity provides a read-out of" exact="ZIKV" post="RVP entry into cells [55,56]. Data from this experiment"/>
  <result pre="consistent with earlier reports that NT50 titres obtained with recombinant" exact="ZIKV" post="RVPs and wild-type ZIKVs are comparable [55,56]. Analysing single"/>
  <result pre="All individual sera tested manifested comparable NT50 titres in the" exact="ZIKV" post="RVP virus neutralisation assay, with the difference in maximal"/>
  <result pre="also determined the nAb titres against each of the four" exact="DENV" post="serotypes using a flow cytometry-based assay [51]. Interestingly, this"/>
  <result pre="Determination of recall nAb response in immunised mice using the" exact="ZIKV" post="luciferase reporter assay. (a) Determination of ZIKV nAb titre"/>
  <result pre="mice using the ZIKV luciferase reporter assay. (a) Determination of" exact="ZIKV" post="nAb titre in the same pooled immune serum as"/>
  <result pre="pooled immune serum as in Fig. 3d, but determined using" exact="ZIKV" post="RVPs. The data are represented as percent infection (in"/>
  <result pre="as percent infection (in terms of Renilla luciferase activity of" exact="ZIKV" post="RVPs) as a function of immune serum dilution, with"/>
  <result pre="a function of immune serum dilution, with luciferase activity of" exact="ZIKV" post="RVP in absence of immune serum taken to represent"/>
  <result pre="horizontal line in both panels denotes 50% infection based on" exact="ZIKV" post="RVP luciferase activity. Can this ZIKV-specific nAb response be"/>
  <result pre="dose (Supplementary File, Fig. S6), for nAb estimation using the" exact="ZIKV" post="RVP luciferase assay. This experiment, the results of which"/>
  <result pre="immune serum also failed to neutralise any of the four" exact="DENV" post="serotypes (Supplementary File, Fig. S6, table on the right)."/>
  <result pre="This suggests that memory recall preserves the absolute specificity for" exact="ZIKV" post="and does not expand to DENVs. That the antibody"/>
  <result pre="the question: what is the contribution of EDIII-specific antibodies to" exact="ZIKV" post="neutralising activity? To address this, we depleted EDIII-specific antibodies"/>
  <result pre="titres, strongly suggest a significant role for EDIII-specific antibodies in" exact="ZIKV" post="neutralisation. Fig. 5 Depletion of EDIII-specific antibodies from anti-ZIKV-80E"/>
  <result pre="antibodies from anti-ZIKV-80E NP antiserum is accompanied by reduction in" exact="ZIKV" post="nAb titres. (a) Pooled serum (n = 5) collected"/>
  <result pre="(on days 0, 14, 28, and 160) was analysed for" exact="ZIKV" post="EDIII-specific antibody titres by indirect ELISA using MBP-ZIKV EDIII"/>
  <result pre="The pooled serum described in panel ‘a’ was assayed for" exact="ZIKV" post="nAb titres either before (solid curve) or after (dashed"/>
  <result pre="after (dashed curve) depletion on amylose resin-bound MBP-ZIKV EDIII using" exact="ZIKV" post="RVP neutralisation assay. Note that in this experiment, MBP-depleted"/>
  <result pre="as percent infection (in terms of Renilla luciferase activity of" exact="ZIKV" post="RVPs) as a function of immune serum dilution, with"/>
  <result pre="a function of immune serum dilution, with luciferase activity of" exact="ZIKV" post="RVP in absence of immune serum taken to represent"/>
  <result pre="100% infection. The dashed horizontal line denotes 50% inhibition of" exact="ZIKV" post="reporter activity. 3.4 Antibodies elicited by ZIKV-80E NPs offer"/>
  <result pre="protection in vivo Can the anti-ZIKV-80E NP antibodies which block" exact="ZIKV" post="infectivity in vitro be effective in countering lethal ZIKV"/>
  <result pre="block ZIKV infectivity in vitro be effective in countering lethal" exact="ZIKV" post="infection in vivo? To address this question, we used"/>
  <result pre="used C57BL/6 Stat2−/− mice, which are not only susceptible to" exact="ZIKV" post="infection, but also display several key aspects of ZIKV"/>
  <result pre="to ZIKV infection, but also display several key aspects of" exact="ZIKV" post="pathogenesis. When challenged with ZIKV MR766 (103 PFU/mouse), these"/>
  <result pre="display several key aspects of ZIKV pathogenesis. When challenged with" exact="ZIKV" post="MR766 (103 PFU/mouse), these mice lose body weight starting"/>
  <result pre="then challenged 2 h later with a lethal dose of" exact="ZIKV" post="MR766 strain (103 PFU/mouse), and monitored for 15 days"/>
  <result pre="comprised of mice which received neither serum transfer nor lethal" exact="ZIKV" post="inoculation (‘Un-infected’). On day 4 post-challenge, mice were bled"/>
  <result pre="inoculation (‘Un-infected’). On day 4 post-challenge, mice were bled and" exact="ZIKV" post="RNA levels determined by RT-qPCR. The resultant viremia data,"/>
  <result pre="viremia data, presented in Fig. 6b, revealed that, the mean" exact="ZIKV" post="RNA level in the α-ZIKV-80E (200 µl) group was"/>
  <result pre="µl) group was ∼3 logs lower, compared to the mean" exact="ZIKV" post="RNA levels in the groups which received 10-fold lower"/>
  <result pre="serum at 200 µl/mouse failed to confer protection against lethal" exact="ZIKV" post="challenge, with all mice succumbing by post-challenge day 8."/>
  <result pre="antiserum [α-ZIKV-80E (200 µl) group] were protected when challenged with" exact="ZIKV" post="MR766. This was statistically significant, compared to the survival"/>
  <result pre="manifest clear evidence of a dose-dependent protective effect against lethal" exact="ZIKV" post="challenge. Fig. 6 Evaluation of the capacity of ZIKV-80E"/>
  <result pre="ZIKV-80E NP-induced antibodies to protect C57BL/6 Stat2−/− mice against lethal" exact="ZIKV" post="MR766 challenge. (a) Schematic depiction of the efficacy test"/>
  <result pre="(200 µl)’ group, n = 4] and challenged i.d. with" exact="ZIKV" post="MR766 (103 PFU/mouse). A fourth group of mice, which"/>
  <result pre="for comparison. Mice were bled on day 4 post-challenge for" exact="ZIKV" post="RNA determination. All mice were monitored for the criteria"/>
  <result pre="Blood plasma viral RNA levels (ZIKV genome copies/ml plasma) in" exact="ZIKV" post="MR766-challenged mice, determined by q-RTPCR on day 4 post-challenge"/>
  <result pre="control in the in vitro ADE assay, we used the" exact="DENV" post="cross-reactive pan-flavivirus-specific mAb 4G2. This mAb, specific to the"/>
  <result pre="resulted in ADE of infection for each of the four" exact="DENV" post="serotypes. This was evident from the typical bell-shaped infection"/>
  <result pre="concentration during the pre-incubation step, for each of the four" exact="DENV" post="serotypes (Fig. 7a). Qualitatively similar, but relatively greater, levels"/>
  <result pre="antiserum also had the ability to cross-neutralise the remaining three" exact="DENV" post="serotypes as well (NT50 titres against DENVs-1, −3 and"/>
  <result pre="was discernible in K562 cells for any of the four" exact="DENV" post="serotypes (Fig. 7c). Interestingly, none of the DENVs could"/>
  <result pre="(102 to 105) tested (Fig. 7d). Fig. 7 Evaluation of" exact="DENV" post="infection-enhancement by anti-ZIKV-80E NP antiserum. (a) Each of the"/>
  <result pre="infection-enhancement by anti-ZIKV-80E NP antiserum. (a) Each of the four" exact="DENV" post="serotypes was separately pre-incubated with different amounts of mAb"/>
  <result pre="concentration. (b) Similar experiment as in panel ‘a’, except that" exact="DENV" post="pre-incubations were performed with pooled, serially diluted (10−1–10−5) immune"/>
  <result pre="(twin star symbol). That anti-ZIKV-80E NP antibodies did not enhance" exact="DENV" post="infection is notable. How relevant are the data on"/>
  <result pre="are diluted down to sub-neutralising levels [59]. What if the" exact="ZIKV" post="nAb titres were to wane to sub-neutralising level? Would"/>
  <result pre="to sub-neutralising level? Would it result in homotypic ADE of" exact="ZIKV" post="infection? Thus, a final question we addressed was whether"/>
  <result pre="repertoire induced by ZIKV-80E NPs could potentially cause enhancement of" exact="ZIKV" post="infection in vivo, under conditions of sub-neutralising nAb levels."/>
  <result pre="end, we used C57BL/6 Stat2−/− mouse model, in conjunction with" exact="ZIKV" post="strain PRVABC59. Infection with this ZIKV strain, which is"/>
  <result pre="model, in conjunction with ZIKV strain PRVABC59. Infection with this" exact="ZIKV" post="strain, which is least pathogenic to this model, can"/>
  <result pre="can be escalated to severe disease, in the presence of" exact="DENV" post="immune serum, marked by significant weight loss, enhanced clinical"/>
  <result pre="expected NT50 &amp;lt;10) and challenged them 2 h later with" exact="ZIKV" post="strain PRVABC59, administered i.d. For comparison, groups of mice"/>
  <result pre="clinical symptoms and weight loss, succumbing by day 8 post" exact="ZIKV" post="challenge. On the other hand, survival of mice which"/>
  <result pre="NPs, at sub-neutralising levels, may not be capable of enhancing" exact="ZIKV" post="infection. However, it is to be noted that the"/>
  <result pre="vivo relevance of the FcR pathway, in the context of" exact="ZIKV" post="infection is unknown at this time. Fig. 8 Evaluation"/>
  <result pre="infection is unknown at this time. Fig. 8 Evaluation of" exact="ZIKV" post="infection-enhancement by anti-ZIKV-80E NP antiserum. C57BL/6 Stat2−/− mice were"/>
  <result pre="(mouse α-ZIKV-80E, solid purple squares) and then challenged with live" exact="ZIKV" post="(PRVABC59, 5 × 103 PFU/mouse, i.d.) two hours later."/>
  <result pre="One group of mice which received neither immune serum nor" exact="ZIKV" post="inoculation (Un-infected, solid brown squares) was included for comparison."/>
  <result pre="or as significant (twin star symbol). 4 Discussion An effective" exact="ZIKV" post="vaccine continues to be actively sought [17,[26], [27], [28],"/>
  <result pre="[29], [30]]. These initiatives exploit multiple strategies and platforms for" exact="ZIKV" post="vaccine development. Of the many potential vaccine platforms available,"/>
  <result pre="NPs, which were highly immunogenic, displayed EDIII prominently, based on" exact="DENV" post="EDIII-specific mAb-probing analyses, as well as the predominantly EDIII-focused"/>
  <result pre="if ZIKV-80E when expressed in P. pastoris, would assemble into" exact="ZIKV" post="EDIII-displaying NPs with similar attributes. The elimination of the"/>
  <result pre="may also be advantageous. Though it is not known if" exact="ZIKV" post="prM antibodies may have a role in ADE, like"/>
  <result pre="prM antibodies may have a role in ADE, like their" exact="DENV" post="counterparts, this cannot be entirely ruled out given that"/>
  <result pre="pups born to ZIKV-immune mice [60] and macaques pre-infected with" exact="ZIKV" post="[61] manifest signs of ADE of DENV infection. Thus,"/>
  <result pre="macaques pre-infected with ZIKV [61] manifest signs of ADE of" exact="DENV" post="infection. Thus, it is preferable to eliminate prM from"/>
  <result pre="a small panel of six mAbs. Four of these were" exact="ZIKV" post="EDIII-specific conformational mAbs, the fifth mAb specific to EDIIIs"/>
  <result pre="EDIII-specific conformational mAbs, the fifth mAb specific to EDIIIs of" exact="ZIKV" post="as well as DENVs, and the sixth mAb specific"/>
  <result pre="subtle differences between the prM-lacking ZIKV-80E NP and the prM-containing" exact="ZIKV" post="particle could be inferred from the mAb probing analysis."/>
  <result pre="the EDIII C–C’ loop which is not accessible on the" exact="ZIKV" post="particle, is accessible on the ZIKV-80E NP, as evidenced"/>
  <result pre="the ZIKV-80E NPs. This has implications for vaccine safety as" exact="ZIKV" post="FLE-specific antibodies have been reported to mediate ADE of"/>
  <result pre="their ability to display EDIII, the ZIKV-80E NPs elicited predominantly" exact="ZIKV" post="EDIII-specific total antibody titres (log10 serum titres, &amp;gt;5). Importantly,"/>
  <result pre="EDIII display platform, in the light of recent findings that" exact="ZIKV" post="EDIII displayed on Hepatitis B surface antigen VLP platform"/>
  <result pre="platform elicited much lower nAb titres, by comparison [48]. Many" exact="ZIKV" post="vaccine development studies, investigating multiple delivery formats have consistently"/>
  <result pre="delivery formats have consistently and compellingly demonstrated that protection against" exact="ZIKV" post="challenge is dependent on ZIKV-specific nAbs [17,31,47,[63], [64], [65],"/>
  <result pre="ZIKV-specific nAbs [17,31,47,[63], [64], [65], [66]]. Experiments in mice with" exact="ZIKV" post="prM+E DNA vaccine candidates have shown that log10 serum"/>
  <result pre="shown that log10 serum antibody titres ≥2.35, specific to recombinant" exact="ZIKV" post="E, and ZIKV-specific nAb titres &amp;gt;10 can confer effective"/>
  <result pre="ZIKV-specific nAb titres &amp;gt;10 can confer effective protection against live" exact="ZIKV" post="challenge [65]. In contrast, another study using ZIKV prM+E"/>
  <result pre="against live ZIKV challenge [65]. In contrast, another study using" exact="ZIKV" post="prM+E VLPs found that NT50 ≥125 protects mice against"/>
  <result pre="≥125 protects mice against lethal challenge [63]. A purified inactivated" exact="ZIKV" post="vaccine that could elicit nAb titres of NT50 ∼100"/>
  <result pre="titres of NT50 ∼100 was capable of conferring protection against" exact="ZIKV" post="challenge in mice [66]. By these criteria, we surmise"/>
  <result pre="conferred on C57BL/6 Stat2−/− challenged with a lethal dose of" exact="ZIKV" post="MR766 by passively transferred anti-ZIKV-80E NP antiserum was dose-dependent."/>
  <result pre="has an inherent limitation in that it only simulates waning" exact="ZIKV" post="nAb titres. Assuming that the 200 µl immune serum"/>
  <result pre="Assuming that the 200 µl immune serum (NT50 titre against" exact="ZIKV" post="MR766=461), passive-transferred per mouse, undergoes ∼12-fold dilution (assuming a"/>
  <result pre="of ∼2.5 ml/mouse), one may argue that the resulting circulating" exact="ZIKV" post="NT50 titre of ∼36 affords 50% protection against lethal"/>
  <result pre="under different experimental conditions, using different animal models and different" exact="ZIKV" post="challenge viruses. For example, using either DNA-based ZIKV vaccine"/>
  <result pre="and different ZIKV challenge viruses. For example, using either DNA-based" exact="ZIKV" post="vaccine or a purified inactivated ZIKV vaccine, some investigators"/>
  <result pre="example, using either DNA-based ZIKV vaccine or a purified inactivated" exact="ZIKV" post="vaccine, some investigators have actively immunised BALB/c or AG129"/>
  <result pre="protective efficacy following challenge with Brazilian, Puerto Rican or African" exact="ZIKV" post="strains, in terms of either suppression of viremia or"/>
  <result pre="One study which used passive transfer of immune sera from" exact="ZIKV" post="prM+E VLP vaccinated CB6F1 mice, into AG129 mice as"/>
  <result pre="mice as we did, however used a Nicaraguan strain of" exact="ZIKV" post="for challenge [63]. Standardisation of the efficacy assay will"/>
  <result pre="will help meaningful comparison of different vaccine candidates. As severe" exact="ZIKV" post="infection is associated with fetal abnormalities, it would be"/>
  <result pre="has a genetic defect in the innate immune signalling pathway." exact="ZIKV" post="vaccine development is complicated by the existence of the"/>
  <result pre="existence of the ADE phenomenon, stemming from the interaction between" exact="ZIKV" post="on the one hand and DENVs on the other"/>
  <result pre="also are genetically and antigenically similar. DENV-antibodies which cross-react with" exact="ZIKV" post="can enhance its uptake via Fcγ-R pathway, to increase"/>
  <result pre="can enhance its uptake via Fcγ-R pathway, to increase tissue" exact="ZIKV" post="load. Likewise, anti-ZIKV antibodies from ZIKV-infected humans can cross-react"/>
  <result pre="promote their uptake into Fcγ-R-bearing cells, contributing to increased tissue" exact="DENV" post="load. While epidemiological data in support of this is"/>
  <result pre="this is currently not available, recent experiments have demonstrated that" exact="ZIKV" post="mAbs specific to EDI/II from ZIKV-infected patients can enhance"/>
  <result pre="in vivo[32]. Thus, a potential safety attribute of a future" exact="ZIKV" post="vaccine is that, in addition to eliciting adequate levels"/>
  <result pre="levels of virus-nAbs, it must not contribute to ADE of" exact="DENV" post="infection, especially in the current situation when DENV infections"/>
  <result pre="ADE of DENV infection, especially in the current situation when" exact="DENV" post="infections continue to occur in the absence of new"/>
  <result pre="DENV infections continue to occur in the absence of new" exact="ZIKV" post="infections. Our data showed that ZIKV-80E NPs induced DENV"/>
  <result pre="new ZIKV infections. Our data showed that ZIKV-80E NPs induced" exact="DENV" post="cross-reactive, but non-neutralising antibodies. Would these antibodies enhance DENV"/>
  <result pre="induced DENV cross-reactive, but non-neutralising antibodies. Would these antibodies enhance" exact="DENV" post="infection? That they may not is evident from the"/>
  <result pre="anti-ZIKV-80E NP antibodies at low levels might possibly possess homotypic" exact="ZIKV" post="infection-enhancing potential. However, passive transfer of anti-ZIKV-80E NP antiserum"/>
  <result pre="dilution, lowering nAb titres to sub-neutralising levels), followed by live" exact="ZIKV" post="(strain PRVABC59) challenge, did not exacerbate morbidity and mortality"/>
  <result pre="that the EDIII-focused anti-ZIKV antibodies do not possess any homotypic" exact="ZIKV" post="infection-enhancing activity in vivo, even at very low concentrations."/>
  <result pre="caution while extrapolating vaccine efficacy in the mouse model to" exact="ZIKV" post="infection in humans. That P. pastoris expressed ZIKV-80E can"/>
  <result pre="eliminates any potential safety concern relating to ADE of both" exact="ZIKV" post="as well as DENVs. Further, in the absence of"/>
  <result pre="by ZIKV-80E NPs lack ADE potential, in vivo, both towards" exact="DENV" post="as well as ZIKV. To our knowledge, this is"/>
  <result pre="well as ZIKV. To our knowledge, this is the first" exact="ZIKV" post="vaccine candidate to demonstrate lack of ADE in vivo."/>
  <result pre="system [70,71] using inexpensive media is another advantage of this" exact="ZIKV" post="vaccine candidate. Taken together, the data justify further research"/>
  <result pre="ZIKV-80E-based NP vaccine to evaluate its utility as a possible" exact="ZIKV" post="subunit vaccine candidate. Data availability All data generated or"/>
  <result pre="ed.2013Wolters Kluwer and Lippincott Williams &amp;amp; WilkinsPhiladelphia747794 2PiersonT.C.DiamondM.SThe emergence of" exact="Zika" post="virus and its new clinical syndromesNature560201857358130158602 3GathererD.KohlAZika virus: a"/>
  <result pre="emergence in the Western hemisphereJ Virol9020164864487526962217 5MussoD.RocheC.RobinE.NhanT.TeissierA.Cao-LormeauV.MPotential sexual transmission of" exact="Zika" post="virusEmerg Infect Dis21201535936125625872 6BesnardM.LastèreS.TeissierA.Cao-LormeauV.M.MussoDEvidence of perinatal transmission of Zika"/>
  <result pre="of Zika virusEmerg Infect Dis21201535936125625872 6BesnardM.LastèreS.TeissierA.Cao-LormeauV.M.MussoDEvidence of perinatal transmission of" exact="Zika" post="virus, French Polynesia, December 2013 and February 2014Euro Surveill19132014pii=20751."/>
  <result pre="virus associated with microcephalyN Engl J Med374201695195826862926 8BaudD.GublerD.J.SchaubB.LanteriM.C.MussoDAn update on" exact="Zika" post="virus infectionLancet39020172099210928647173 9LesslerJ.ChaissonL.H.KucrkaL.M.Assessing the global threat from Zika virusScience3532016aaf8160"/>
  <result pre="update on Zika virus infectionLancet39020172099210928647173 9LesslerJ.ChaissonL.H.KucrkaL.M.Assessing the global threat from" exact="Zika" post="virusScience3532016aaf8160 10RasmussenS.A.JamiesonD.J.HoneinM.A.PetersenL.RZika virus and birth defects-reviewing the evidence for"/>
  <result pre="virus and microcephalyN Engl J Med374201698498526862812 12CalvetG.AguiarR.S.MeloA.S.O.Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
  <result pre="a case studyLancet Infect Dis16201665366026897108 13Cao-LormeauV.M.BlakeA.MonsS.Guillain-Barre syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control studyLancet38720161531153926948433 14TangH.HammackC.OgdenS.C.Zika"/>
  <result pre="attenuates their growthCell Stem Cell18201658759026952870 15MessinaJ.P.KraemerM.U.G.BradyO.J.Mapping global environmental suitability for" exact="Zika" post="viruseLife52016e1527227090089 16FergusonN.M.CucunubaZ.M.DorigattiI.Countering the Zika epidemic in Latin AmericaScience353201635335427417493 17AbbinkP.StephensonK.E.BarouchD.HZika"/>
  <result pre="Cell18201658759026952870 15MessinaJ.P.KraemerM.U.G.BradyO.J.Mapping global environmental suitability for Zika viruseLife52016e1527227090089 16FergusonN.M.CucunubaZ.M.DorigattiI.Countering the" exact="Zika" post="epidemic in Latin AmericaScience353201635335427417493 17AbbinkP.StephensonK.E.BarouchD.HZika virus vaccinesNature162018594600 18collab: The"/>
  <result pre="virus vaccinesNature162018594600 18collab: The Lancet Infectious Diseases Editorial BoardVaccine against" exact="Zika" post="virus must remain a priorityLancet Infect Dis1720181003 19TaylorA.FooS.S.BruzzoneR.DinhL.V.KingN.J.C.MahalingamSImmunol Rev268201534036426497532"/>
  <result pre="in socio-economically distinct areas of Recife, BrazilActa Trop113201023424019896921 24BardinaS.V.BunducP.TripathiS.Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunityScience356201717518028360135 25DejnirattisaiW.SupasaP.WongwiwatW.Dengue virus sero-cross-reactivity"/>
  <result pre="immunityScience356201717518028360135 25DejnirattisaiW.SupasaP.WongwiwatW.Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with" exact="Zika" post="virusNat Immunol1720161102110827339099 26PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJDevelopment of vaccines against Zika virusLancet Infect"/>
  <result pre="of infection with Zika virusNat Immunol1720161102110827339099 26PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJDevelopment of vaccines against" exact="Zika" post="virusLancet Infect Dis182018e211e21929396004 27Wilder-SmithA.VanniceK.DurbinA.Zika vaccines and therapeutics: landscape analysis"/>
  <result pre="therapeutics: landscape analysis and challenges aheadBMC Med1620188429871628 28BarrettA.D.TCurrent status of" exact="Zika" post="vaccine development: Zika vaccines advance into clinical evaluationnpj Vaccines320182429900012"/>
  <result pre="and challenges aheadBMC Med1620188429871628 28BarrettA.D.TCurrent status of Zika vaccine development:" exact="Zika" post="vaccines advance into clinical evaluationnpj Vaccines320182429900012 29RichnerJ.M.DiamondM.SZika virus vaccines:"/>
  <result pre="Health OrganizationVaccine pipeline tracker2020https://docs.google.com/spreadsheets/d/19otvINcayJURCMg76xWO4KvuyedYbMZDcXqbyJGdcZM/pubhtml#Accessed 24st Feb 2020 31ZhaoH.FernandezE.DowdK.A.Structural basis of" exact="Zika" post="virus-specific antibody protectionCell16620161016102727475895 32StettlerK.BeltramelloM.EspinosaD.A.Specificity, cross-reactivity, and function of antibodies"/>
  <result pre="antibody protectionCell16620161016102727475895 32StettlerK.BeltramelloM.EspinosaD.A.Specificity, cross-reactivity, and function of antibodies elicited by" exact="Zika" post="virus infectionScience353201682382627417494 33WangQ.YangH.LiuX.Molecular determinants of human neutralizing antibodies isolated"/>
  <result pre="of human neutralizing antibodies isolated from a patient infected with" exact="Zika" post="virusSci Transl Med82016369ra179 34DaiL.SongJ.LuX.Structures of the Zika virus envelope"/>
  <result pre="patient infected with Zika virusSci Transl Med82016369ra179 34DaiL.SongJ.LuX.Structures of the" exact="Zika" post="virus envelope protein and its complex with a flavivirus"/>
  <result pre="antibodyCell Host Microb192016696704 35SirohiD.ChenZ.SunL.The 3.8 Å resolution cryo-EM structure of" exact="Zika" post="virusScience352201646747027033547 36KostyuchenkoV.A.LimE.X.Y.ZhangS.Structure of the thermally stable Zika virusNature533201642542827093288 37YuanL.HuangX.Y.LiuZ.Y.A"/>
  <result pre="cryo-EM structure of Zika virusScience352201646747027033547 36KostyuchenkoV.A.LimE.X.Y.ZhangS.Structure of the thermally stable" exact="Zika" post="virusNature533201642542827093288 37YuanL.HuangX.Y.LiuZ.Y.A single mutation in the prM protein of"/>
  <result pre="Zika virusNature533201642542827093288 37YuanL.HuangX.Y.LiuZ.Y.A single mutation in the prM protein of" exact="Zika" post="virus contributes to fetal microcephalyScience358201793393628971967 38ScreatonG.MongkolsapayaJEvolution of neurovirulent Zika"/>
  <result pre="of Zika virus contributes to fetal microcephalyScience358201793393628971967 38ScreatonG.MongkolsapayaJEvolution of neurovirulent" exact="Zika" post="virusScience358201786386429146794 39SalvoM.A.Kingstad-BakkeB.Salas-QuinchucuaC.CamachoE.OsorioJ.EZika virus like particles elicit protective antibodies in"/>
  <result pre="Trop Dis112017e0005608 41GargH.SedanoM.PlataG.PunkeE.B.JoshiADevelopment of virus-like-particle vaccine and reporter assay for" exact="Zika" post="virusJ Virol912017e00834–17 42UrakamiA.TunM.M.N.MoiM.L.An envelope-modified tetravalent dengue virus-like particle vaccine"/>
  <result pre="vaccine has implications for flavivirus vaccine designJ Virol912017e01181–17 43ManiS.TripathiL.RautR.Pichia pastoris-expressed" exact="Dengue" post="2 envelope forms virus-like particles without pre-membrane protein and"/>
  <result pre="protein and induces high titer neutralizing antibodiesPLoS One82013e6459523717637 44TripathiL.ManiS.RautR.Pichia pastoris-expressed" exact="Dengue" post="3 envelope-based virus-like particles elicit predominantly domain III-focused high"/>
  <result pre="titer neutralizing antibodiesFront Microbiol62015100526441930 45PoddarA.RamasamyV.ShuklaR.Virus-like particles derived from Pichia pastoris-expressed" exact="Dengue" post="virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain"/>
  <result pre="glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodiesBMC Biotechnol1620165027301568 46KhetarpalN.ShuklaR.RajpootR.K.Recombinant" exact="Dengue" post="virus 4 envelope glycoprotein virus-like particles derived from Pichia"/>
  <result pre="neutralizing antibodiesAm J Trop Med Hyg96201712613427821688 47SapparapuG.FernandezE.KoseN.Neutralizing human antibodies prevent" exact="Zika" post="virus replication and fetal disease in miceNature540201644344727819683 48ShanmugamR.K.RamasamyV.ShuklaR.AroraU.SwaminathanS.KhannaNPichia pastoris-expressed"/>
  <result pre="Zika virus replication and fetal disease in miceNature540201644344727819683 48ShanmugamR.K.RamasamyV.ShuklaR.AroraU.SwaminathanS.KhannaNPichia pastoris-expressed" exact="Zika" post="virus envelope domain III on a virus-like particle platform:"/>
  <result pre="dependent enhancement in AG129 micePLoS Negl Trop Dis122018e0006191 50TripathiS.BalasubramaniamV.R.M.T.BrownJ.A.A novel" exact="Zika" post="virus mouse model reveals strain specific differences in virus"/>
  <result pre="a novel reporter virus neutralization test for serological diagnosis of" exact="Zika" post="and dengue virus infectionJ Clin Microbiol5520173028303628768729 56ShanC.XieX.RenP.A rapid Zika"/>
  <result pre="of Zika and dengue virus infectionJ Clin Microbiol5520173028303628768729 56ShanC.XieX.RenP.A rapid" exact="Zika" post="diagnostic assay to measure neutralizing antibodies in patientsEBioMed172017157162 57ShuklaR.RajpootR.K.AroraU.PoddarA.SwaminathanS.KhannaNPichia"/>
  <result pre="miceSci Rep82018864329872153 59PiersonT.C.XuQ.NelsonS.The stoichiometry of antibody-mediated neutralization and enhancement of" exact="West Nile" post="virus infectionCell Host Microbe1200713514518005691 60FowlerA.M.TangW.W.YoungM.P.Maternally acquired Zika antibodies enhance"/>
  <result pre="enhancement of West Nile virus infectionCell Host Microbe1200713514518005691 60FowlerA.M.TangW.W.YoungM.P.Maternally acquired" exact="Zika" post="antibodies enhance Dengue disease severity in miceCell Host Microbe24201874375030439343"/>
  <result pre="Nile virus infectionCell Host Microbe1200713514518005691 60FowlerA.M.TangW.W.YoungM.P.Maternally acquired Zika antibodies enhance" exact="Dengue" post="disease severity in miceCell Host Microbe24201874375030439343 61GeorgeJ.ValiantW.G.MattapallilM.J.Prior exposure to"/>
  <result pre="Dengue disease severity in miceCell Host Microbe24201874375030439343 61GeorgeJ.ValiantW.G.MattapallilM.J.Prior exposure to" exact="Zika" post="virus significantly enhances peak Dengue-2 viremia in Rhesus macaquesSci"/>
  <result pre="proteinPLoS One92014e100641 63EspinosaD.MendyJ.ManayaniD.Passive transfer of immune sera induced by a" exact="Zika" post="virus-like particle vaccine protects AG129 mice against lethal Zika"/>
  <result pre="a Zika virus-like particle vaccine protects AG129 mice against lethal" exact="Zika" post="virus challengeEBioMedicine272018617029269041 64AbbinkP.LaroccaR.A.De La BarreraR.A.Protective efficacy of multiple vaccine"/>
  <result pre="challengeEBioMedicine272018617029269041 64AbbinkP.LaroccaR.A.De La BarreraR.A.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysScience35320161129113227492477 65LaroccaR.A.AbbinkP.PeronJ.P.S.Vaccine protection against Zika"/>
  <result pre="against Zika virus challenge in rhesus monkeysScience35320161129113227492477 65LaroccaR.A.AbbinkP.PeronJ.P.S.Vaccine protection against" exact="Zika" post="virus from BrazilNature536201647447827355570 66SumathyK.KulkarniB.GonduR.K.Protective efficacy of Zika vaccine in"/>
  <result pre="65LaroccaR.A.AbbinkP.PeronJ.P.S.Vaccine protection against Zika virus from BrazilNature536201647447827355570 66SumathyK.KulkarniB.GonduR.K.Protective efficacy of" exact="Zika" post="vaccine in AG129 mouse modelSci Rep720174637528401907 67BrownJ.A.SinghG.AcklinJ.A.Dengue virus immunity"/>
  <result pre="vaccine in AG129 mouse modelSci Rep720174637528401907 67BrownJ.A.SinghG.AcklinJ.A.Dengue virus immunity increases" exact="Zika" post="virus-induced damage during pregnancyImmunity50201911230650369 68CulshawA.MongkolsapayaJ.ScreatonG.RThe immunopathology of dengue and"/>
  <result pre="Zika virus-induced damage during pregnancyImmunity50201911230650369 68CulshawA.MongkolsapayaJ.ScreatonG.RThe immunopathology of dengue and" exact="Zika" post="virus infectionsCurrent Opin Immunol48201716 69HarrisonS.CImmunogenic cross-talk between dengue and"/>
  <result pre="Zika virus infectionsCurrent Opin Immunol48201716 69HarrisonS.CImmunogenic cross-talk between dengue and" exact="Zika" post="virusesNature Immunol1720161010101227540984 70VoglT.HartnerF.S.GliederANew opportunities by synthetic biology for biopharmaceutical"/>
 </snippets>
</snippetsTree>
